Shvetank Bhatt

Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage

Ankur Jindal, Radhakrishnan Mahesh, Shvetank Bhatt · Pharmacology Biochemistry and Behavior · 2013 · 55 citations

Stress Hormone, Psychiatry, Stress +11

Green biogenic silver nanoparticles, therapeutic uses, recent advances, risk assessment, challenges, and future perspectives

Sumel Ashique, Aakash Upadhyay, Afzal Hussain et al. · Journal of Drug Delivery Science and Technology · 2022 · 45 citations

Nanoparticles, Nanomedicine, Risk Assessment +11

Potential of postbiotics for the treatment of metabolic disorders

Neeraj Mishra, Ashish Garg, Sumel Ashique et al. · Drug Discovery Today · 2024 · 38 citations

Prebiotics, Probiotic, Metabolic Disorder +8

Discovery of new anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides

Radhakrishnan Mahesh, Thangaraj Devadoss, Dilip Pandey et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 29 citations · Full text

Pharmacological Study, Medicine, Pharmacological Agent +5

Design, synthesis and structure–activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression

Radhakrishnan Mahesh, Thangaraj Devadoss, Dilip Pandey et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 24 citations · Full text

Structure–activity Relationship, Medicinal Chemistry, Medicine +9